How Wide Do Lumpectomy Margins Really Need to Be? A Major New Trial Weighs In

If you’ve had a lumpectomy for DCIS, you probably remember waiting on your pathology report — and hoping for the words “clear margins.” Many patients also remember the follow-up conversation: what happens if the margin, the rim of healthy tissue around the removed tissue, comes back narrower than your surgeon would like? For years, the answer has often been a second surgery. A large new analysis of a major randomized trial suggests that answer may be due for a second look.

Why Margin Width Has Been Such a Big Deal

A “margin” is the distance between the edge of the DCIS and the edge of the tissue removed during surgery. Since 2016, U.S. clinical practice has followed a 2-millimeter margin guideline from the Society of Surgical Oncology (SSO), American Society of Clinical Oncology (ASCO), and American Society for Radiation Oncology (ASTRO): patients with margins narrower than 2 mm are often advised to have a re-excision — an additional surgery to remove more tissue — before starting radiation. That guideline was based on a meta-analysis of mostly retrospective studies, not a randomized trial designed to test the question directly.

The stakes of getting this right are real. One study found that after the 2-mm guideline was adopted, re-excision rates rose from about 20% to 30%, and the rate of patients converting to full mastectomy nearly quadrupled. For anyone facing a “narrow margin” conversation with their surgeon, that’s not an abstract statistic — it’s the difference between one surgery and two, or between breast conservation and mastectomy.

What This New Study Looked At

The analysis, published July 1, 2026, in JAMA Surgery, comes from the NSABP B-35 trial — to date, the largest randomized trial to prospectively collect margin-width data in DCIS. The original trial enrolled 3,104 postmenopausal women with hormone receptor–positive DCIS, all of whom had lumpectomy, whole-breast radiation, and five years of hormone therapy (either tamoxifen or anastrozole). Because pathologists recorded exact margin widths for every patient at the time of surgery, researchers were later able to go back and ask a question the original trial wasn’t designed to answer: did narrower margins actually predict a higher risk of the cancer coming back in the same breast?

What the Researchers Found

Using two thresholds — 1 mm and 2 mm — the researchers compared 10-year recurrence rates:

At the 1-mm threshold, women with margins narrower than 1 mm had a 5.6% rate of local recurrence at 10 years, compared with 4.0% for those with margins of 1 mm or wider — an absolute difference of 1.6 percentage points. At the 2-mm threshold (the current guideline), the rates were 5.3% versus 3.8% — a 1.5-point difference. Both differences were small but statistically detectable on their own.

The more telling result came next. Once the researchers accounted for other factors known to influence recurrence risk — patient age, tumor size, and which hormone therapy was used — margin width was no longer a statistically significant predictor of recurrence at all. In other words, once you control for the bigger drivers of risk, the margin itself carried far less weight than the guideline’s binary cutoff suggests. The researchers also looked at all breast cancer events combined (not just same-breast recurrence) and found no meaningful difference by margin width there either.

What This Could Mean for Patients

The study’s authors were direct about the implication: “Omission of reexcision lumpectomies based on margin widths of less than 1 mm or less than 2 mm can be reconsidered in appropriate patients.” That’s a meaningful statement from one of the largest and most rigorous datasets available on this question — though it comes with important caveats.

This analysis was conducted in postmenopausal women with hormone receptor–positive DCIS who received both radiation and hormone therapy — it doesn’t tell us about premenopausal women, hormone receptor–negative disease, or patients skipping radiation or endocrine therapy. And because margin width itself wasn’t randomly assigned in the trial, this remains an observational comparison, not a head-to-head test of “re-excise vs. don’t.” The researchers are careful to frame their conclusion around personalized decision-making, not a blanket new rule.

Still, for many patients, this is a hopeful development. It adds real, prospectively collected evidence to a conversation that’s long relied on retrospective data — and it supports what a growing number of breast cancer specialists have been saying: a narrow-but-negative margin, in the right clinical context, may not automatically require another trip to the operating room.

The Bottom Line

If you’re weighing a re-excision decision — or wondering whether your own narrow margin means added risk — this is exactly the kind of research worth bringing to your care team. Margin width is just one piece of a much bigger picture that includes your age, tumor size, hormone receptor status, and treatment plan. The most important takeaway from this study may be that DCIS treatment decisions are moving further away from one-size-fits-all rules and closer to conversations tailored to each patient’s full picture.